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Plasmapheresis in Treatment of 
Myasthenia Gravis
Valerii Voinov
Abstract
Treatment of myasthenia gravis is still a rather difficult task, since there is no 
single tactic to use different drugs (corticosteroids, rituximab, immunoglobulins), 
especially since it is associated with a number of side effects. They are not able to 
remove the accumulating autoantibodies and immune complexes, the large size of 
which does not allow them to be excreted by the kidneys as well. Special problems 
of treatment arise when myasthenic crises develop associated with respiratory 
failure requiring artificial lungs ventilation. Plasmapheresis can help to solve this 
for it is possible to remove antibodies and other pathological metabolites. In addi-
tion, regular plasmapheresis is able not only to prevent exacerbations but also to 
reduce doses of the maintenance therapy with less risk of their side effects, which is 
confirmed by our own experience.
Keywords: myasthenia gravis, autoimmunity, autoantibodies, drug therapy, 
plasmapheresis
1. Introduction
Myasthenia gravis (MG) is a relatively rare disease, affecting about 140 people 
per million [1, 2]; however, its frequency has been increasing in the recent years, 
especially in the elderly population with mortality rate of 0.27/100,000 people, and 
in intensive care units, mortality of such patients reaches 5.3% [3, 4]. However, MG 
also affects children, manifesting in three forms: transient neonatal myasthenia, 
congenital myasthenic syndrome, and juvenile MG [5]. In the latter case, the disease 
onset can be from 11 months to 17 years [6]. Although the disease has been known 
for decades, a single tactic of its treatment has not yet been developed. In many 
respects, it depends on the variety of forms and their etiopathogenetic features. In 
particular, the main focus is on the use of drug therapy, and too little attention is 
paid to plasmapheresis. Therefore, the main objective of this study is to justify the 
need for plasmapheresis in the treatment of MG.
2. Etiology and pathogenesis
MG is a long-term neuromuscular disease that leads to various degrees of the 
skeletal muscles weakness. The most commonly affected muscles are those of 
the eyes, face, and swallowing [7]. In this case, IgG antibodies appear to nicotine 
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acetylcholine (ACh) receptors of the postsynaptic membrane, which leads to the 
muscle weakness increase [8]. In some cases, antibodies can also emerge to the 
muscle-specific kinase (MuSK) [9]. In this case, antibodies against MuSK can 
produce plasmoblasts, and in such cases, removal of B-lymphocytes does not 
exclude recurrence of MG [10]. It also does not exclude autoantibodies presence to 
other postsynaptic proteins (anti-titin, anti-integrin antibodies) in small amounts 
[11–13].
3. Drug therapy
3.1 Cholinesterase inhibitors
Cholinesterase inhibitors (pyridostigmine bromide) delay the disease progres-
sion and increase the availability of ACh on the motor end membranes and lead to 
their strength increase [14]. Cholinergic side effects, including hyperactivation of 
the smooth muscles of the urinary bladder and intestines causing diarrhea, abdomi-
nal cramps, increased salivation, sweating, and bradycardia, are dose limiting and 
lead to noncompliance to the treatment plan [15].
3.2 Corticosteroids
The most common tactic for MG treatment is based on corticosteroids therapy 
[16]. However, such therapy is not deprived of a large number of adverse reactions. 
They lead to Cushingoid syndrome. Glucocorticoids, in particular, are diabetogenic 
hormones for they suppress glucose consumption by the tissues, and its production 
by the liver becomes increased. Besides, they can also directly suppress the release of 
insulin, thus showing that β-cells of pancreatic islets are one of their targets. Other 
complication of long glucocorticoid therapy is osteoporosis. It is considered that these 
hormones inhibit proliferation and differentiation of osteoblasts and stimulate 
their apoptosis. There is also an indirect mechanism of bones resorption caused 
by secondary hyperparathyreosis due to intestinal calcium adsorption decrease. 
Glucocorticoids effect on hypothalamus and gonads causes hypogonadism [17]. 
Development of chronic inflammatory polyneuropathy is also described [18]. There 
are evidences about correlation between such intensive and prolonged immunosup-
pressive therapy and the onset of tumors [19, 20].
3.3 Immunoglobulins
Administration of large doses of immunoglobulins does lead to such serious 
complications as aseptic meningitis, hemolytic anemia, cardiac rhythm disorders, 
and neurologic frustration in children with thrombotic thrombocytopenic purpura. 
Arthritis, thromboembolic complications, vasculitis, and a systemic lupus erythe-
matosus are the side effects of autoantibodies and circulating immune complexes. 
Besides, there are other complications such as lethal hypersensitive (allergic) myo-
carditis and refractory heart failure, rash and skin itch, a leucopenia, a neutropenia, 
fever, etc. [21–24]. Presence of immune complexes may be the cause of it [25]; how-
ever, the main cause that must be recognized is the technology of immunoglobulins 
preparation from thousands (!) of donors having different blood types with full set 
of anti-A and anti-B isohemagglutinins (α and β), which lead to destruction of the 
corresponding erythrocytes [26]. At the same time, plasma exchange was necessary 
to relieve such hemolytic complication [27].
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3.4 Rituximab
In the recent years, treatment of autoimmune diseases with rituximab—chime-
ric monoclonal antibody to CD20 antigen of B-lymphocytes—has become rather 
widespread, which should reduce the production of autoantibodies [28]. Rituximab 
is believed to be the first choice therapy [7]. Nevertheless, there are also complica-
tions of such treatment described leading even to fulminant hepatitis and multiple 
organ failure development [28–30]. Rituximab, cetuximab, and panitumumab have 
direct nephrotoxic effect [31]. Rituximab and alemtuzumab are reported to cause 
interstitial pneumonia development [32]. Prospectively, after rituximab treatment, 
neutropenia with pneumonia and other infectious complications may develop in 
up to 17% [33, 34]. There are reports about development of male infertility due to 
either gonadal dysfunction or antisperm autoantibodies production [35]. In addi-
tion, as noted above, removal of B-cells is not always accompanied by decrease in 
the autoantibodies reproduction [10].
4. Plasmapheresis
Considering the disease autoimmune nature, direct removal of antibodies by 
plasmapheresis is more effective [9, 36–38]. It causes normalization of immuno-
globulin levels and reduction of the circulating immune complexes (CICs) in 1.7–2 
times. The overall subjective improvement is observed in 94% of patients after a 
primary set of five plasma exchange procedures with their addition if necessary 
[39]. In severe cases, patients can be quickly disconnected from the artificial lung 
ventilation, but it is a relatively short-term effect and requires repeated sets of 
procedures [40].
Nevertheless, along with plasmapheresis, the same results are obtained by 
intensive intravenous immunoglobulin administration at a dose of 0.4 g/kg daily 
for 3 or 5 days [41, 42]. Though, using intensive plasmapheresis, we can achieve 
better results in the treatment of myasthenic crises, rather than by intravenous 
administration of immunoglobulins, the course of which costs $78.814 [43–47]. 
Immunoadsorption methods are also used; however, the best results are achieved in 
combination with plasma exchange [16].
It is advisable to carry out three to five procedures of plasmapheresis with 
removal of plasma up to 2.0–2.5 ml/kg of the body weight [48]. It is also possible to 
carry out daily procedures of plasma exchange removing smaller amounts of plasma, 
instead of the abovementioned plasma exchange, being carried out every other day 
[49]. Similarly, plasma exchange provides faster positive effect (already after the first 
procedure) in patients resistant to rituximab [50]. Nevertheless, carrying out plasma 
exchange along with rituximab treatment appeared more effective [51].
Plasmapheresis before thymectomy greatly facilitates the postoperative period 
[52–55]. Moreover, in cases when thymoma recurs postoperatively after a course of a 
plasma exchange, its involution is observed [56].
In juvenile forms of MG, plasmapheresis with immunoglobulins appears suc-
cessful [57, 58], and it was noted that plasma exchange yields more stable results than 
IVIG therapy [44].
It should be noted that in the earliest symptoms of MG such as weakness of the 
cervical paraspinal muscles (dropped head syndrome), plasma exchange and immu-
noadsorption are justified [59].
The use of specific IgG-immunoadsorption to remove antibodies to ACh receptors 
[60] seems prospective as well as new systems for cascade plasmapheresis [53, 61]. 
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At a cascade plasma exchange, the level of soluble molecules of intercellular adhesion 
decreases more effectively and the quantity of the T-regulating cells increases [62]. 
After a cascade plasma exchange, they observe increase in the SatO2 levels associated 
with decrease in pCO2 [63].
Nevertheless, in the comparable groups of patients with MG, there were no 
significant differences noted in the effectiveness of immunoadsorption or cascade 
plasmapheresis [64, 65]. On the other hand, there were no benefits found of 
immunoglobulin transfusions before cascade plasmapheresis or immunoadsorp-
tion [66]. After a cascade plasma exchange, they also noted a decrease in cytotoxic 
activity of the natural killer cells that even more improves the effectiveness of such 
treatment [67].
MG development is also possible in infants due to “graft-versus-host” disease 
(GVHD) following bone marrow transplantation. The course of plasmapheresis 
with subsequent administration of immunoglobulins was quite effective [68].
Our own experience shows that there are two possible applications of plasma-
pheresis. In myasthenic crises accompanied by swallowing and breathing disorders 
when patients need artificial lung ventilation, it is really necessary to urgently 
conduct a massive plasma exchange, removing 1–1.5 of the total plasma volume 
(TPV) with compensation with albumin and fresh frozen donor plasma for four to 
five procedures every day or every other day [69, 70]. The same tactic is described in 
the American Society for Apheresis Guidelines on the Use of Therapeutic Apheresis 
in Clinical Practice [71].
Then, to achieve a more stable remission, it is necessary to repeat procedures 
of less massive plasmapheresis at intervals of 2–4 weeks, removing only 0.3–0.5 
TPV. The same tactic is used in less severe degrees of the disease, when the removed 
plasma volume can be compensated only by crystalloid solutions. In this case, the 
primary course also consists of four such plasmapheresis procedures, followed by 
one procedure every 1–2 months. Given the fact that MG can be observed in young 
children up to the development of myasthenic crises, it is desirable to use equip-
ment with a small volume of filling. In our practice, we use a device for membrane 
plasmapheresis called “Hemophenix” (“Trackpore Technology,” Russia) with an 
internal filling volume up to 70 ml, which can be used even in unstable hemody-
namics, including in children. The advantage is a single-needle access using any 
peripheral vein.
Our practice includes 15 patients with MG. Two of them were in acute stage of 
the myasthenic crisis with respiratory failure, requiring connection to artificial 
lungs ventilation. One of them was a girl of 8 years old, who had complication 
of GVHD on the background of lymphocytic leukemia. She had already been on 
artificial lung ventilation for 10 days without visible effect (Figure 1). After two 
procedures of plasma exchange in a volume of 1.2 TPV, she was already able to 
breathe herself. In total, five such procedures were performed with a good effect of 
restoring the motor activity except for some left eyelid ptosis, which persisted after 
a month (Figure 2). The second patient had been on the artificial lung ventilation 
for 2 weeks in one of the clinics in Sofia, Bulgaria (Figure 3). Also, after two plasma 
exchange procedures, it was possible to switch him off the artificial lung ventilation 
(Figure 4), and after the last fourth procedure, he was already able to move without 
assistance and was discharged from the clinic.
The other patients were in different degrees of MG severity, and they per-
formed a conventional plasmapheresis in the volume of 0.3–0.5 TPV with replace-
ment of the removed plasma with an isotonic solution of sodium chloride. The 
course of treatment consisted of four such procedures, conducted every other day. 
Most of the procedures were performed in outpatient settings. The main task was 
to stabilize the condition and prevent the disease recurrence. One of them was in 
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Figure 1. 
Girl M of 8 years old and 18 kg body weight. Myasthenic crisis with artificial ventilation for 10 days. Plasma 
exchange using the “Hemophenix” device.
Figure 2. 
The same girl a month after the course of plasma exchange.
Figure 3. 
Patient T of 28 years old. The first session of plasma exchange on the device “Hemophenix” on the background 
of artificial lung ventilation, carried out for 2 weeks.
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quite serious condition and was able to move only with someone’s assistance. After 
the primary course of plasmapheresis, we followed the tactics of a “programmed” 
plasmapheresis once per month, which enabled him to return to his physical work 
of an auto mechanic. The follow-up period is 6 years.
5. Conclusion
The autoimmune nature of the disease undoubtedly is an indication for plas-
mapheresis since it is the only way to remove large-molecule pathological products 
(autoantibodies, immune complexes) that cannot be excreted by the kidneys. Our 
experience shows that after such courses of plasmapheresis, conducted twice a year, 
it is possible to practically reduce the doses of corticosteroids and other medicines 
by half and, thereby, avoid the toxic consequences of their use.
Figure 4. 
The same patient after two sessions of plasma exchange. Disconnected from the ventilator.
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